Compounds of the formula ##STR1## where X is O or S; R.sub.1 is lower alkyl having 1 to 6 carbons; R.sub.2 is H, lower alkyl having 1 to 6 carbons; or OR.sub.2.sup.* where R.sub.2.sup.* is lower alkyl having 1 to 6 carbons; Y is O, S or NH; and R.sub.3 is H, lower alkyl having 1 to six carbons, or C(O)R.sub.3.sup.* where R.sub.3.sup.* is lower alkyl having 1 to 5 carbons, with the proviso that the YR.sub.3 group is not disposed in the ortho position on the benzene nucleus relative to the 2-amino group of the oxazoline or thiazoline heterocycle, are active in maintaining or reducing intraocular pressure in the mammalian eye, and are active as vasoconstrictors and capable of reducing or controlling intraocular bleeding of the mammalian eye.

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

A dissolvable backing layer for use with transmucosal drug delivery devices includes a dissolvable hydrophilic region and a non-hydrophilic region that inhibits or slows migration of water, drugs, other active agents, or other molecules through the backing layer. The non-hydrophilic region can be a disperse phase of gaseous voids, droplets of a hydrophobic liquid, solid particles of a hydrophobic material, or water insoluble particles that are not necessarily hydrophobic. In the alternative, the non-hydrophilic region may comprise a continuous layer or component that is readily dispersible upon dissolving of the hydrophilic region. The backing layers may be used within any transmucosal delivery device used to delivery drugs or other active agents across a mucosal surface.

A water-dissolvable drug delivery device designed so as to reliably maintain a drug or active agent within a defined region against a mucosal surface. The drug delivery device comprises a water-dissolvable backing layer, an adhesive layer adjacent to at least a portion of the backing layer, and an active layer that is circumscribed by the backing layer and adhesive layer. The backing layer may optionally include a water-dissolvable hydrophilic region and a non-hydrophilic region at least partially encapsulated within the hydrophilic region that inhibits migration of water, drugs, or other active agents through the backing layer. The adhesive layer may be water-activated or it may have a peelable cover layer that, when removed, exposes the adhesive material. The active layer may comprise any drug or other active agent, either alone or in combination with (i) an enhancer that increases the ability of the drug or other active agent to diffuse through a mucosal membrane and/or (ii) a matrix material such as an alginate to hold the active layer together.